US Asset Management LLC Takes Position in Eli Lilly and Company (NYSE:LLY)

US Asset Management LLC purchased a new position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 1,592 shares of the company's stock, valued at approximately $928,000. Eli Lilly and Company makes up about 0.9% of US Asset Management LLC's holdings, making the stock its 29th largest position.

A number of other institutional investors also recently modified their holdings of LLY. Simon Quick Advisors LLC boosted its position in shares of Eli Lilly and Company by 10.5% during the 4th quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company's stock valued at $1,706,000 after purchasing an additional 278 shares in the last quarter. Clear Harbor Asset Management LLC bought a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $363,000. Terril Brothers Inc. boosted its position in shares of Eli Lilly and Company by 113.2% during the 4th quarter. Terril Brothers Inc. now owns 808 shares of the company's stock valued at $471,000 after purchasing an additional 429 shares in the last quarter. Hartline Investment Corp boosted its position in shares of Eli Lilly and Company by 1.1% during the 4th quarter. Hartline Investment Corp now owns 21,934 shares of the company's stock valued at $12,786,000 after purchasing an additional 248 shares in the last quarter. Finally, Commonwealth Equity Services LLC boosted its position in shares of Eli Lilly and Company by 5.2% during the 4th quarter. Commonwealth Equity Services LLC now owns 354,565 shares of the company's stock valued at $206,683,000 after purchasing an additional 17,461 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Price Performance

NYSE:LLY traded down $11.29 during mid-day trading on Friday, reaching $760.26. The stock had a trading volume of 2,081,716 shares, compared to its average volume of 3,060,203. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. Eli Lilly and Company has a one year low of $419.80 and a one year high of $800.78. The stock has a market capitalization of $722.55 billion, a P/E ratio of 113.12, a P/E/G ratio of 1.45 and a beta of 0.37. The firm has a 50 day moving average price of $761.92 and a two-hundred day moving average price of $676.24.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The company had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. During the same period in the previous year, the company posted $1.62 earnings per share. The firm's revenue was up 26.0% on a year-over-year basis. As a group, analysts expect that Eli Lilly and Company will post 13.82 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Thursday, May 16th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.68%. Eli Lilly and Company's dividend payout ratio is currently 76.58%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on LLY shares. Erste Group Bank upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Wednesday, April 3rd. Wells Fargo & Company upped their price target on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 6th. DZ Bank downgraded Eli Lilly and Company from a "buy" rating to a "hold" rating and set a $820.00 price target on the stock. in a research note on Wednesday, February 21st. Barclays upped their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 7th. Finally, Truist Financial upped their price target on Eli Lilly and Company from $850.00 to $892.00 and gave the stock a "buy" rating in a research note on Wednesday, May 1st. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of "Moderate Buy" and a consensus target price of $757.95.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.